A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
Recruiting
Phase 1
Interventional Study
Huntington's Disease
At a Glance
- Age
- 25 – 70
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 66 (estimated)
- Sponsor
- Alnylam Pharmaceuticals · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria
* Has stage 2 or early Stage 3 Huntington's disease (HD), per the Huntington's Disease Integrated Staging System (HD-ISS)
Exclusion Criteria
* Has significant structural or degenerative neurologic disease other than Huntington's Disease (HD) at screening
* Has primary or second…
Contacts